Korean Journal of Stroke 2012 ; 14 (2) : p.62~66
New Antithrombotics
(뇌졸중 최신지견 2011: 새로운 항혈전제)
저자 서권덕,이경열
논문 종류 Review Articles 전문 보기 KJS-14-62-66.pdf

Several new antithrombotic drugs have been developed and approved to use in clinical practice recently. Dabigatran, a direct thrombin inhibitor, and rivaroxaban, a factor Xa inhibitor, have been approved in many countries including Korea to prevent stroke in patient with atrial fibrillation. Apixaban, another factor Xa inhibitor, showed good results in clinical trial and is waiting for approval for clinical use. New antiplatelet agent, terutroban, selective thromboxane A2 receptor inhibitor, failed to prove the efficacy over the aspirin in secondary stroke prevention. Vorapaxar, a new antiplatelet agent that inhibits thrombin through PAR-1 antagonism, showed a high incidence of intracranial hemorrhage in patient with a history of stroke. (Korean J Stroke 2012;14:62-66)

KEY WORDS: Atrial fibrillation, Anticoagulant, Antiplatelet agent, Ischemic stroke